Trusted Resource for Clinical Trials, Protocols & Progress
Unlike full-service CROs, FSPs are embedded in sponsor operations but report independently. KPIs provide quantifiable insights into their productivity, quality, and compliance.
Click to read the full article.
In an FSP arrangement, sponsors outsource specific functions while maintaining ownership of trial strategy, systems, and outcomes. However, sponsors remain accountable under ICH-GCP and regulatory frameworks such as those set forth by the USFDA and CDSCO. Proper oversight ensures:
Click to read the full article.
Organizations consider transitioning to FSPs for several reasons:
Click to read the full article.
Scalability in trials refers to the sponsor’s ability to:
Click to read the full article.
Multiple vendors across functions—e.g., one for CRAs, another for data management, and yet another for medical writing—create numerous challenges:
Click to read the full article.
Niche CROs are specialized service providers that focus on a limited number of therapeutic areas, modalities, or trial phases. Unlike full-service CROs, niche CROs emphasize:
Click to read the full article.
Unlike high-prevalence indications, rare disease studies demand CROs that can:
Click to read the full article.
A specialty CRO is a contract research organization that focuses on a specific therapeutic area (e.g., oncology, rare diseases), a development phase (e.g., early phase), or a unique clinical function (e.g., data management, pharmacovigilance). Unlike full-service CROs, they provide targeted, often boutique-level, services tailored to a narrow domain.
Click to read the full article.
CROs typically operate under one or more of the following financial models:
Click to read the full article.
Unlike pharmaceutical products, devices and diagnostics are evaluated based on mechanical, software, and functional performance in addition to clinical safety and effectiveness. Key differentiators include:
Click to read the full article.
